gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · JANXHealthcarePharmaceuticals

Janux Therapeutics, Inc. Common Stock (JANX)

$16.06−11.66%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$17.02▼ 36.99% in range
Nov 4, 2025Low $12.18 · High $34.74Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Janux Therapeutics closed at $16.06 on Nov 5, down 11.66%, 53.8% below its 52-week closing high. Volume of 894.5K shares was 1.18× its 20-day average (close to normal).

Split-adjusted performance: -10.4% over one month, +10.5% over six months, -40.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $10.27M, with a net margin of -214.0%.

Short interest was 5.3M shares at the Oct 15 settlement, down 6.3% from the prior report (11.8% of float, 6.2 days to cover).

Market cap$981.9M61.1M shares
Revenue · quarter$10.3M—
Diluted EPS$-0.35—
P/E · TTM—P/S 40.9×
Net margin-214.0%Gross 100.0%
Dividend yieldNone
52-week range12.18 – 34.74−53.8% from high
Volume894.5K1.18× 20-day avg
Volatility · 60d54.2%Annualised
Short % of float11.8%6.2 days to cover
Net cash$970.9MCash $970.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −9.9%1M −10.4%3M +1.3%6M +10.5%YTD +16.4%1Y −40.5%3Y +150.2%5Y −33.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum81
Revenue growth—
Net margin39
Value (low P/E)—
Size71

Industry medians: 6-month return −28.4%, revenue growth +5.9%, net margin −38.9%, P/E 15.0×.

Short interest

Details →
Shares short5.3M−6.3% vs prior
Days to cover6.2Settled Oct 15
% of float11.8%
Short vol. 10d41.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
JANXJanux Therapeutics$16.06−11.66%+10.5%—−214.0%—$981.9M
HROWHarrow$26.04−9.43%−33.3%+10.9%−24.4%—$976.2MCompare
MRVIMaravai LifeSciences Holdings$6.98−9.59%+77.2%+8.5%−24.1%—$1.04BCompare
MLTXMoonLake Immunotherapeutics$10.80−6.57%−37.2%———$919.2MCompare
SVRASavara$4.38−6.01%−15.1%———$899.9MCompare
JBIOJade Biosciences$14.10−6.25%−41.8%———$896.7MCompare
SPTXSeaport Therapeutics$20.39−2.72%————$1.09BCompare
ORICOric Pharmaceuticals$8.49−9.10%−3.6%———$880.0MCompare
LTGOLatigo Biotherapeutics$13.01−7.34%————$862.6MCompare

News about Janux Therapeutics

All news →

No recent articles focused on Janux Therapeutics. 3 articles mention it in passing.

Quick answers

What does Janux Therapeutics do?
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.
What is JANX's market cap?
$981.86M, based on the Nov 5 close of $16.06.
Does Janux Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of JANX is sold short?
5.3M shares, 11.8% of float, as of Oct 15, 2026.
What sector is JANX in?
Healthcare, in the Pharmaceuticals industry.

About Janux Therapeutics

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

HQ: San Diego, CA113 employeesListed Jun 11, 2021januxrx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology